is there any greater possibility in finding hla-identical unrelated hematopoietic stem cell donors among thalassemia families for transplantation of thalassemia patients?

نویسندگان

m mohyeddin hematology- oncology and bmt research center, shariati hospital, tehran, iran

p alijanipour hematology- oncology and bmt research center, shariati hospital, tehran, iran

k alimoghaddam hematology- oncology and bmt research center, shariati hospital, tehran, iran

a ghavamzadeh hematology- oncology and bmt research center, shariati hospital, tehran, iran

چکیده

background: thalassemia is probably the most common single gene disorder causing a major public health problem in the world. currently, allogenic hematopoietic stem cell transplantation (hsct) is the only curative therapy for thalassemia. one major limitation of hsct is the lack of hla-identical sibling donors, so attention has turned to finding phenotypically matched unrelated donors. patients and methods: from 1991 to 2002, 182 thalassemia patients referred to our center for hsct. donor selection was based on hla class i and class ii histocompatibility matching. the results of the serologically hla class i typing of 549 subjects (patients and their families) and hla class ii typing of 182 patients were compared with hla class i and ii antigens of 100 healthy iranians normal people. the comparisons between these two groups were tested in univariate analysis, using the pearson chi-squared statistics. results: in comparing, thalassemic families (549 subjects) and healthy iranians (100 subjects) for hla class i antigens, significant differences for 11 antigens, including a9 (p= 0.029), a11 (p= 0.01), a19 (p= 0.000), b16 (p= 0.000), b17 (p= 0.029), b27 (p= 0.003), b41(p= 0.000), c2 (p= 0.015), c3(p= 0.012), c4 (p= 0.004), c7 (p= 0.000) were found. for hla class ii antigens, we found that only hla-dr7 was significantly different (p= 0.002) between 182 thalas-semia patients and the healthy iranian normal group. conclusion: in this study, we found that thalassemia families showed significant differences, compared to the healthy iranian group in several hla antigens. comparing hla polymorphism and finding enough similarity in thalassemia families in the countries, located in the thalassemia belt, may provide benefits for establishing a common hla bank of thalassemia families.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Hematopoietic Stem Cell Transplantation for Thalassemia

Thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin. For β-thalassemia major patients, therapeutic options are either monthly red cell transfusions and chelation therapy or allogeneic stem cell transplant. Stem cell transplant is the only curative approach and success is inversely correlated with the degree of iron overload and h...

متن کامل

hematopoietic stem cell transplantation for thalassemia

thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin. for β-thalassemia major patients, therapeutic options are either monthly red cell transfusions and chelation therapy or allogeneic stem cell transplant. stem cell transplant is the only curative approach and success is inversely correlated with the degree of iron overload and h...

متن کامل

Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients

BACKGROUND Beta thalassemia major is a severe inherited form of hemolytic anemia that results from ineffective erythropoiesis. Allogenic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative therapy. Unfortunately, the subgroup of adult thalassemia patients with hepatomegaly, portal fibrosis and a history of irregular iron chelation have an elevated risk for trans...

متن کامل

Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia.

The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplant...

متن کامل

What Unrelated Hematopoietic Stem Cell Transplantation in Thalassemia Taught us about Transplant Immunogenetics

Although the past few decades have shown an improvement in the survival and complication-free survival rates in patients with beta-thalassemia major and gene therapy is already at an advanced stage of experimentation, hematopoietic stem cell transplantation (HSCT) continues to be the only effective and realistic approach to the cure of this chronic non-malignant disease. Historically, human leu...

متن کامل

Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors.

Allogeneic hematopoietic stem cell transplantation (HSCT) is a proven curative therapy for many hematologic malignancies. HSCT from HLA-identical sibling donors (ISDs) is still the golden standard. For the remaining 70% of the patients lacking an ISD, alternative (partially) HLA-matched family donors (MFDs) and HLA-matched unrelated donors (MUDs) are now widely accepted. However, it is presentl...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of hematology-oncology and stem cell research

جلد ۱، شماره ۱، صفحات ۲۴-۲۷

کلمات کلیدی

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023